Skip to main content

Table 1 Patients’ clinical and pathologic characteristics

From: Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy—validation of a prediction model

Characteristicsn = 292 
Age at PET/CT, median (years) 70 (IQR 65–74)
Primary Gleason score at RP≤ 7204 (69.9%)
≥ 888 (30.1%)
Pathologic primary tumour stage (pT)≤ pT2c140 (47.9%)
≥ pT3a152 (52.1%)
Pathologic regional lymph node stage (pN)pN0230 (78.8%)
pN162 (21.2%)
Additional treatment after RP1 142 (48.6%)
 Radiation therapy 107 (36.6%)
 ADT (within the last 6 months) 35 (12.0%)
PSA value prior to PET/CT, median (ng/ml) 0.50 (IQR 0.35–0.70)
 0.2–0.5 ng/ml (very low)n = 1510.35 (IQR 0.27–0.43)
 > 0.5–1.0 ng/ml (low)n = 1410.71 (IQR 0.60–0.90)
  1. ADT androgen deprivation therapy, RP radical prostatectomy
  2. 1Multiple secondary treatments within a patient possible